We next analyzed the CPI1000+ data split by cancer/drug type, assessing four groupings where we had two or more independent cohorts available: melanoma anti-PD-1/L1, melanoma anti-CTLA-4, urothelial carcinoma anti-PD-1/L1, and non-small cell lung cancer anti-PD-1/L1. The gene discussed is CTLA4; the disease is urothelial carcinoma.